This result is highly significant because the observed effect size with BHB/citrate supplementation far exceeds the effect size of pharmacological intervention with vasopressin receptor antagonists in PKD rodent models that underpinned the development of tolvaptan as an approved therapy for ADPKD.
← all excerpts
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease.
1
—
—